Drug susceptibility evaluation of an influenza a(h7n9) virus by analyzing recombinant neuraminidase proteins

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S566-S574

  Gubareva, Larisa V ^a   Sleeman, Katrina ^a,b   Guo, Zhu ^a   Yang, Hua ^a   Hodges, Erin ^a,b   Davis, Charles T ^a   Baranovich, Tatiana ^a,b   Stevens, James ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b Carter Consulting Incorporated   (Georgia)

Author keywords

A(H7N9); bird flu; Drug resistance; Neuraminidase; Recombinant protein

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RECOMBINANT PROTEIN; SIALIC ACID; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; SIALIDASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME INHIBITION; IC50; INFLUENZA A VIRUS (H7N9); NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC DATABASE; GENETICS; HUMAN; INFLUENZA, HUMAN; MULTIDRUG RESISTANCE; PROTEIN CONFORMATION;

ANTIVIRAL AGENTS; CYCLOPENTANES; DATABASES, GENETIC; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; NEURAMINIDASE; OSELTAMIVIR; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; VIRAL PROTEINS; ZANAMIVIR;

EID: 85030612549     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw625     Document Type: Article

References (47)

1. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97.
2. Lam TT, Zhou B, Wang J, et al. Dissemination, divergence and establishment of H7N9 influenza viruses in China. Nature 2015; 522:102-5.
3. Pantin-Jackwood MJ, Miller PJ, Spackman E, et al. Role of poultry in the spread of novel H7N9 influenza virus in China. J Virol 2014; 88:5381-90.
4. Zhu H, Lam TT, Smith DK, Guan Y. Emergence and development of H7N9 influenza viruses in China. Curr Opin Virol 2016; 16:106-13.
5. Zhang Y, Shen Z, Ma C, et al. Cluster of human infections with avian influenza A (H7N9) cases: A temporal and spatial analysis. Int J Environ Res Public Health 2015; 12:816-28.
6. William T, Thevarajah B, Lee SF, et al. Avian influnza (H7N9) virus infection in Chinese tourist in Malaysia, 2014. Emerg Infect Dis 2015; 21:142-5.
7. Yang JR, Kuo CY, Huang HY, et al. Characterization of influenza A (H7N9) viruses isolated from human cases imported into Taiwan. PLoS One 2015; 10:e0119792.
8. Skowronski DM, Chambers C, Gustafson R, et al. Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015. Emerg Infect Dis 2016; 22:71-4.
9. Centers for Disease Control and Prevention. Interim guidance on the use of antiviral agents for treatment of human infections with avian influenza A (H7N9) virus. http://www.cdc.gov/flu/avianflu/h7n9-Antiviral-Treatment.htm. Accessed July 28 2016.
10. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953-6.
11. Cohen M, Zhang XQ, Senaati HP, et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J 2013; 10:321.
12. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004; 78:12665-7.
13. Shtyrya YA, Mochalova LV, Bovin NV. Influenza virus neuraminidase: structure and function. Acta Naturae 2009; 1:26-32.
14. Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995; 4:1081-7.
15. Collins PJ, Haire LF, Lin YP, et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009; 27:6317-23.
16. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67:2972-80
17. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 2012; 17(1 Pt B):159-73.
18. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012; 87:369-74.
19. World Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors. http://www.who.int/influenza/gisrs-laboratory/antiviral-susceptibility/avwg2014 nai substitution table.pdf?ua=1. Accessed July 29 2016.
20. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006; 11:971-6
21. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-9.
22. Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-Treated patient in Taiwan. J Infect Dis 2015; 211:249-57.
23. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013; 19:1521-4.
24. Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio 2013; 4.
25. Mok CK, Chang SC, Chen GW, et al. Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus. J Microbiol Immunol Infect 2015; 48:465-9.
26. Itoh Y, Shichinohe S, Nakayama M, et al. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. Antimicrob Agents Chemother 2015; 59:4962-73
27. Zaraket H, Baranovich T, Kaplan BS, et al. Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck. Nat Commun 2015; 6:6553.
28. Kuhnel K, Jarchau T, Wolf E, et al. The VASP tetramerization domain is a righthanded coiled coil based on a 15-residue repeat. Proc Natl Acad Sci U S A 2004; 101:17027-32.
29. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 2008; 82:10493-501.
30. Okomo-Adhiambo M, Mishin VP, Sleeman K, et al. Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance. Antiviral Res 2016; 128:28-35
31. Chayen NE, Stewart PDS, Blow DM. Microbatch crystallization under oil-A new technique allowing many small-volume crystallization trials. Journal of Crystal Growth 1992; 122:176-80.
32. Otwinowski Z, Minor W. Processing of X-ray Diffraction Data Collected in Oscillation Mode.In: Carter CW Jr, Sweet RM, eds. Methods in enzymology. Vol 276. Macromolecular crystallography, part A: Academic Press, 1997:307-26.
33. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 2005; 61(Pt 4):458-64.
34. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60(Pt 12 Pt 1):2126-32
35. Collaborative Computational Project N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994 50 760-3
36. Winn MD, Isupov MN, Murshudov GN. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 2001; 57(Pt 1):122-33.
37. Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX: A comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010; 66(Pt 2):213-21.
38. Davis IW, Leaver-Fay A, Chen VB, et al. MolProbity: All-Atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007; 35(Web Server issue):W375-83.
39. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-9
40. Baker AT, Varghese JN, Laver WG, Air GM, Colman PM. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 1987; 2:111-7.
41. Wang M, Qi J, Liu Y, et al. Influenza A virus N5 neuraminidase has an extended 150-cavity. J Virol 2011; 85:8431-5.
42. Burmeister WP, Ruigrok RW, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992; 11:49-56.
43. Wu Y, Bi Y, Vavricka CJ, et al. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 2013; 23:1347-55.
44. Burmeister WP, Cusack S, Ruigrok RW. Calcium is needed for the thermostability of influenza B virus neuraminidase. J Gen Virol 1994; 75 (Pt 2):381-8.
45. Smith BJ, Huyton T, Joosten RP, et al. Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding. Acta Crystallogr D Biol Crystallogr 2006; 62(Pt 9):947-52.
46. Song MS, Marathe BM, Kumar G, et al. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses. J Virol 2015; 89:10891-900
47. Sleeman K, Mishin VP, Guo Z, et al. Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013. Antimicrob Agents Chemother 2014; 58:2045-51.